Volume Alert - PFE 30.04 Pfizer Inc $PFE Hit a hig
Post# of 190
Posted On: 11/06/2014 11:24:35 PM
Volume Alert - PFE 30.04 Pfizer Inc $PFE Hit a high today of 30.26 Closing the day 11/06/14 at 30.04 unch unch With a day low of 29.97 and a total volume of 16,517,414.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 72.85 (-0.62), PFE: 30.04 (unch)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 44.85 (+4.86), TSLA: 241.22 (+10.25), VRX: 128.77 (-3.14), KR: 57.76 (+0.25), UN: 38.51 (unch), UTX: 108.58 (+0.65), PFE: 30.04 (unch), HAL: 53.17 (+0.80), TAP: 77.05 (+2.89), KORS: 72.31 (-0.09), TLT: 118.39 (-0.77), PEP: 96.81 (-0.08), DFS: 65.69 (+0.86), COH: 33.46 (+0.44), SPY: 203.15 (+0.81), QQQ: 101.69 (+0.32), QCOM: 70.58 (-6.62), DIA: 175.29 (+0.74), COST: 137.09 (+0.59), IWM: 116.53 (+0.50), MSFT: 48.70 (+0.84), CBS: 52.13 (-0.37)
Midday Glance: Pharmaceuticals companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Early Glance: Pharmaceuticals companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.94 (+0.89), PFE: 30.04 (unch), LH: 102.93 (+0.72), ABBV: 62.71 (+0.17), CVD: 101.10 (+0.15)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.84 (-0.46), PFE: 30.04 (unch), AMGN: 160.35 (+1.41), AXN: 0.29 (+0.02), SRNE: 4.60 (-0.01), NKTR: 13.56 (-0.04), EGLT: 6.84 (-0.21), AZN: 72.85 (-0.62), VBAY: ()
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.04 (unch), INCY: 68.40 (+0.68), ONTX: 4.78 (-0.02), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), STML: 14.57 (-0.09), SNTA: 2.86 (+0.02), KBIO: 1.62 (+0.07), BPTH: 2.98 (+0.01), CELGZ: 3.28 (-0.27), NVS: 92.03 (-0.60)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.35 (-0.05), PFE: 30.04 (unch), AZN: 72.85 (-0.62), TTHI: 6.44 (-0.01), TEVA: 58.72 (+0.93), ITCI: 15.47 (+0.28), LLY: 66.96 (-0.03), OMER: 17.28 (+0.04)
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.26 (-0.32), PFE: 30.04 (unch), CVS: 88.43 (+0.93), COST: 137.09 (+0.59), ADBE: 72.10 (+0.73), TYPE: 28.37 (+0.01)
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Business Wire - Wed Nov 05, 10:00AM CST
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
PFE: 30.04 (unch)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.04 (unch), AZN: 72.85 (-0.62), BMY: 58.46 (+0.64)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 6.26 (-0.02), F: 14.19 (+0.25), GE: 26.36 (+0.54), ABX.TO: 12.97 (+0.47), TLM: 5.47 (-0.05), K.TO: 2.54 (+0.27), ABX: 11.34 (+0.37), PFE: 30.04 (unch), HAL: 53.17 (+0.80), AKS: 6.14 (-0.09), BAC: 17.36 (+0.02), T: 34.72 (-0.20), LVLT: 46.36 (-0.48), S: 4.69 (-0.23), KGC: 2.21 (+0.21), TWTR: 40.84 (+0.47)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 39.71 (+0.44), ENDP: 70.19 (+1.49), VRX: 128.77 (-3.14), PFE: 30.04 (unch)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.35 (-0.05), SHPG: 199.95 (+1.34), MRK: 59.26 (-0.31), PFE: 30.04 (unch), SNY: 45.86 (+0.16)
Business Highlights
By The Associated Press - AP - Mon Nov 03, 5:03PM CST
___
JNJ: 109.01 (+0.19), UNH: 96.21 (+0.41), PFE: 30.04 (unch), DRI: 53.10 (+0.41)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Final Glance: Pharmaceuticals companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Will Pfizer Sweeten Its Bid For AstraZeneca?
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Now that the allure of tax inversion deals for U.S. companies has been damped down, Wall Street is wondering if Pfizer (PFE) will sweeten its takeover bid for AstraZeneca (AZN). The new rules "almost entirely remove the benefits," AstraZeneca CEO...
AZN: 72.85 (-0.62), PFE: 30.04 (unch)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 44.85 (+4.86), TSLA: 241.22 (+10.25), VRX: 128.77 (-3.14), KR: 57.76 (+0.25), UN: 38.51 (unch), UTX: 108.58 (+0.65), PFE: 30.04 (unch), HAL: 53.17 (+0.80), TAP: 77.05 (+2.89), KORS: 72.31 (-0.09), TLT: 118.39 (-0.77), PEP: 96.81 (-0.08), DFS: 65.69 (+0.86), COH: 33.46 (+0.44), SPY: 203.15 (+0.81), QQQ: 101.69 (+0.32), QCOM: 70.58 (-6.62), DIA: 175.29 (+0.74), COST: 137.09 (+0.59), IWM: 116.53 (+0.50), MSFT: 48.70 (+0.84), CBS: 52.13 (-0.37)
Midday Glance: Pharmaceuticals companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Early Glance: Pharmaceuticals companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 109.01 (+0.19), BAX: 71.60 (+0.70), PFE: 30.04 (unch), BMY: 58.46 (+0.64)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.94 (+0.89), PFE: 30.04 (unch), LH: 102.93 (+0.72), ABBV: 62.71 (+0.17), CVD: 101.10 (+0.15)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.84 (-0.46), PFE: 30.04 (unch), AMGN: 160.35 (+1.41), AXN: 0.29 (+0.02), SRNE: 4.60 (-0.01), NKTR: 13.56 (-0.04), EGLT: 6.84 (-0.21), AZN: 72.85 (-0.62), VBAY: ()
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.04 (unch), INCY: 68.40 (+0.68), ONTX: 4.78 (-0.02), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), STML: 14.57 (-0.09), SNTA: 2.86 (+0.02), KBIO: 1.62 (+0.07), BPTH: 2.98 (+0.01), CELGZ: 3.28 (-0.27), NVS: 92.03 (-0.60)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.35 (-0.05), PFE: 30.04 (unch), AZN: 72.85 (-0.62), TTHI: 6.44 (-0.01), TEVA: 58.72 (+0.93), ITCI: 15.47 (+0.28), LLY: 66.96 (-0.03), OMER: 17.28 (+0.04)
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.26 (-0.32), PFE: 30.04 (unch), CVS: 88.43 (+0.93), COST: 137.09 (+0.59), ADBE: 72.10 (+0.73), TYPE: 28.37 (+0.01)
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Business Wire - Wed Nov 05, 10:00AM CST
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
PFE: 30.04 (unch)
Why Bristol-Myers Squibb Co. Leaped 15% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 7:46AM CST
BMY data by YCharts What: Shares of big pharma giant Bristol-Myers Squibb shot higher by 15% in October, according to data from S&P Capital IQ , after the company reported better than expected third-quarter earnings results and...
PFE: 30.04 (unch), AZN: 72.85 (-0.62), BMY: 58.46 (+0.64)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 6.26 (-0.02), F: 14.19 (+0.25), GE: 26.36 (+0.54), ABX.TO: 12.97 (+0.47), TLM: 5.47 (-0.05), K.TO: 2.54 (+0.27), ABX: 11.34 (+0.37), PFE: 30.04 (unch), HAL: 53.17 (+0.80), AKS: 6.14 (-0.09), BAC: 17.36 (+0.02), T: 34.72 (-0.20), LVLT: 46.36 (-0.48), S: 4.69 (-0.23), KGC: 2.21 (+0.21), TWTR: 40.84 (+0.47)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 39.71 (+0.44), ENDP: 70.19 (+1.49), VRX: 128.77 (-3.14), PFE: 30.04 (unch)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.35 (-0.05), SHPG: 199.95 (+1.34), MRK: 59.26 (-0.31), PFE: 30.04 (unch), SNY: 45.86 (+0.16)
Business Highlights
By The Associated Press - AP - Mon Nov 03, 5:03PM CST
___
JNJ: 109.01 (+0.19), UNH: 96.21 (+0.41), PFE: 30.04 (unch), DRI: 53.10 (+0.41)
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼